ClinicalTrials.gg
CompletedNCT03042611ANGELUpdated Jul 8, 2022Results posted

A Study to Evaluate Rivoceranib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Participants With Gastric Cancer

A Phase 3 interventional study of Rivoceranib and Placebo in Gastric Cancer and Gastric Adenocarcinoma, sponsored by Elevar Therapeutics. Completed at 95 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-07-08.

Sponsored by Elevar Therapeutics · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
460
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 57 studies testing apatinib in Stomach Neoplasms — 14 open to participants now, 15 under way, 4 of them phase 3. apatinib · Stomach Neoplasms.

Enrollment
3rd of 57
460 · median 47
Started
2017
with 9 others
Phase 3
9 of 57
4 open now
Registered
16th of 57
by date
Lead sponsor
2 of 57
Elevar Therapeutics

Among the 57 studies testing apatinib in Stomach Neoplasms, this one is the 3rd largest by enrollment, is one of 10 that started in 2017, is one of 9 in phase 3, and was the 16th registered.

Stomach Neoplasms

3,403 studies on the registry are indexed under Stomach Neoplasms; 995 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

14 of the 57 studies testing apatinib in Stomach Neoplasms are open now, in 1 country. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About apatinib

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies testing apatinib in Stomach Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of rivoceranib plus best supportive care (BSC) compared to placebo plus BSC in participants with advanced or metastatic gastric cancer (GC).

03

Conditions studied

  • Gastric Cancer
  • Gastric Adenocarcinoma

Keywords

  • Gastric Cancer
  • Gastric Adenocarcinoma
  • Gastro-esophageal Cancer
  • Gastro-esophageal Junction Cancer
  • Stomach Cancer
  • Tumor
  • Oncology
  • Antiangiogenesis
  • Metastatic
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Documented primary diagnosis of histologic- or cytologic-confirmed adenocarcinoma of the stomach or gastroesophageal junction.
  2. Locally advanced unresectable or disease that has progressed since last treatment.
  3. One or more measurable or nonmeasurable evaluable lesions per Version 1.1 (RECIST 1.1).
  4. Failure or intolerance to at least 2 prior lines of standard chemotherapies with each containing one or more of the following agents:

    • fluoropyrimidine (intravenous [IV] 5-fluorouracil [5-FU] capecitabine, or S-1),
    • platinum (cisplatin or oxaliplatin),
    • taxanes (paclitaxel or docetaxel) or epirubicin,
    • irinotecan,
    • trastuzumab in case of human epidermal growth factor receptor 2 ()-positive,
    • ramucirumab
    • nivolumab
    • pembrolizumab
  5. Disease progression within 6 months after the last treatment.
  6. Adequate bone-marrow, renal and liver function.
  7. (ECOG) performance status of ≤1.
  8. Expected survival of ≥12 weeks, in the opinion of the investigator.

Exclusion criteria

Exclusion Criteria:

  1. History of another within 2 years prior to randomization except for the following: Bladder tumors considered superficial such as noninvasive (T1a) and carcinoma in situ (CIS); Curatively treated cervical CIS; Thyroid papillary cancer with prior treatment; Carcinoma of the skin without melanomatous features; Prostate cancer which had been surgically or medically treated and not likely to recur within 2 years.
  2. Central nervous system (CNS) as shown by radiology records or clinical evidence of symptomatic CNS involvement in the last 3 months prior to randomization.
  3. Cytotoxic chemotherapy, surgery, immunotherapy, radiotherapy or other targeted therapies within 3 weeks (4 weeks in cases of ramucirumab, mitomycin C, nitrosourea, lomustine; 1 week in case of ) prior to randomization ( radiotherapy given to local area for non-curative symptom relief is allowed until 2 weeks before randomization.).
  4. Therapy with systemic anticoagulant or antithrombotic agents within 7 days prior to randomization that may prevent blood clotting and, in the investigator's opinion, could place the participant at risk.
  5. Participants who had therapeutic paracentesis of ascites (>1 Liter [L]) within the 3 months prior to starting study treatment or who, in the opinion of the investigator, will likely need therapeutic paracentesis of ascites (>1L) within 3 months of starting study treatment.
  6. Previous treatment with rivoceranib.
  7. Known to rivoceranib or components of the formulation.
  8. Concomitant treatment with strong inhibitors or inducers of , CYP2C9, and CYP2C19.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
460 participants (actual)

Study arms

  • Experimental
    Rivoceranib Plus BSC

    Participants will receive rivoceranib 700 milligrams (mg) orally once per day during each cycle plus BSC. BSC is defined as palliative, non-cancer therapy. Each cycle duration is 28 days.

    Drug: Rivoceranib

  • Experimental
    Placebo

    Participants will receive matching placebo to rivoceranib orally once per day during each cycle plus BSC. BSC is defined as palliative, non-cancer therapy. Each cycle duration is 28 days.

    Drug: Placebo

Interventions

  • Oral tablet

    Also known as: Apatinib

  • DrugPlacebo

    Oral tablet

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    OS was defined as the time from randomization to death. Participants alive or lost to follow-up at the end of study (EOS) were censored.

    Time frame: Day 1 (randomization) up to approximately 36 months

Secondary outcomes

  1. Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)

    PFS was defined as the time from randomization to either documented radiological progression or death from any cause. Participants alive and free of progression at the EOS were censored.

    Time frame: Up to approximately 24 months

  2. Objective Response Rate (ORR) Per RECIST 1.1

    ORR was defined as the percentage of participants in the analysis population with the best overall response of Complete Response (CR: disappearance of all target lesions and reduction in short axis of any nodal target lesions to \<10 millimeter \[mm\]) or a Partial Response (PR: ≥30% decrease in the sum of the longest diameters of the target lesions, taking as a reference the baseline sum diameters) per RECIST 1.1.

    Time frame: Up to approximately 24 months

  3. Disease Control Rate (DCR)

    DCR was defined as the proportion of participants with a Best Overall Response of CR, PR, or stable disease (SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as a reference the smallest sum diameter while on study) per RECIST 1.1.

    Time frame: Up to approximately 24 months

  4. Change From Baseline in Global Health Status/Quality of Life (QoL) Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)

    EORTC QLQ-C30 is a cancer specific Questionnaire with 30 questions for assessing the health-related QOL of cancer participants. The questionnaire incorporates 5 functional scales, 4 symptom scales, a global QOL scale, and single items for the assessment of additional systems commonly reported by cancer participants. All items are scored on 4-point Likert scales, ranging from 1 ('not at all') to 4 ('very much'), with the exception of 2 items in the global QOL scale which use modified 7-point linear analog scales. A linear transformation was used to standardize all scores and single-items to a scale of 0 to 100. For the functioning scales, a higher score indicated greater functioning and for the symptom scales, a higher score indicated a greater symptom burden.

    Time frame: Baseline, End of Treatment (EOT) (Up to 24 months)

  5. Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Stomach Cancer Specific (EORTC QLQ-STO22) Score

    EORTC QLQ-STO22 is a 22-item gastric cancer-specific questionnaire-integrating system for assessing the health-related QOL of gastric cancer participants. Most questions use 4-point scale (1 'Not at all' to 4 'Very much'; 1 question was a yes or no answer). A linear transformation was used to standardize all scores and single-items to a scale of 0 to 100. For the functioning scales, a higher score indicates greater functioning and for the symptom scales, a higher score indicates a greater symptom burden.

    Time frame: Baseline, EOT (Up to 24 months)

  6. Change From Baseline in EuroQol 5-Dimension 5-Level Visual Analogue Scale (EQ-5D-5L VAS) Score

    EQ-5D-5L Questionnaire consists of EQ-5D-5L descriptive system and the visual analogue scale (VAS). The descriptive system comprises the 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and each dimension has 5 levels. The VAS is designed to rate the participant's current health state on a scale from 0 to 100, where 0 represents the worst imaginable health state and 100 represents the best imaginable health state.

    Time frame: Baseline, EOT (Up to 24 months)

  7. Number of Participants Per QOL Dimension Response as Measured by the EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire

    EQ-5D-5L Questionnaire comprises the 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and each dimension has 5 levels of response.

    Time frame: EOT (Month 24)

07

Results

Posted Jul 8, 2022

Participant flow

Core Phase
Participant flow — Core Phase
MilestoneRivoceranib Plus Best Supportive Care (BSC)Placebo Plus BSCExtension Phase: Rivoceranib Plus BSCExtension Phase: Placebo Plus BSC
Started30815200
Received at least 1 dose of study drug30715100
Completed522800
Not completed25612400
Withdrew: Withdrawal by subject13400
Withdrew: Death23211000
Withdrew: Lost to follow-up4700
Withdrew: Physician decision7200
Withdrew: Study closed0100
Extension Phase
Participant flow — Extension Phase
MilestoneRivoceranib Plus Best Supportive Care (BSC)Placebo Plus BSCExtension Phase: Rivoceranib Plus BSCExtension Phase: Placebo Plus BSC
Started005228
Completed0000
Not completed005228
Withdrew: Death003416
Withdrew: Lost to follow-up0011
Withdrew: Study closed001711

Outcome measures

PrimaryOverall Survival (OS)

OS was defined as the time from randomization to death. Participants alive or lost to follow-up at the end of study (EOS) were censored.

Time frame:
Day 1 (randomization) up to approximately 36 months
Reported as:
Median · Months
Overall Survival (OS)
MonthsRivoceranib Plus Best Supportive Care (BSC)Placebo Plus BSC
Overall Survival (OS)5.82 (5.26 to 6.47)5.13 (4.47 to 6.24)
SecondaryProgression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)

PFS was defined as the time from randomization to either documented radiological progression or death from any cause. Participants alive and free of progression at the EOS were censored.

Time frame:
Up to approximately 24 months
Reported as:
Median · Months
Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
MonthsRivoceranib Plus Best Supportive Care (BSC)Placebo Plus BSC
Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)2.83 (2.07 to 3.52)1.77 (1.71 to 1.84)
SecondaryObjective Response Rate (ORR) Per RECIST 1.1

ORR was defined as the percentage of participants in the analysis population with the best overall response of Complete Response (CR: disappearance of all target lesions and reduction in short axis of any nodal target lesions to \<10 millimeter \[mm\]) or a Partial Response (PR: ≥30% decrease in the sum of the longest diameters of the target lesions, taking as a reference the baseline sum diameters) per RECIST 1.1.

Time frame:
Up to approximately 24 months
Reported as:
Number · Percentage of Participants
Objective Response Rate (ORR) Per RECIST 1.1
Percentage of ParticipantsRivoceranib Plus Best Supportive Care (BSC)Placebo Plus BSC
Objective Response Rate (ORR) Per RECIST 1.16.5 (3.74 to 9.25)1.3 (0.16 to 4.67)
SecondaryDisease Control Rate (DCR)

DCR was defined as the proportion of participants with a Best Overall Response of CR, PR, or stable disease (SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as a reference the smallest sum diameter while on study) per RECIST 1.1.

Time frame:
Up to approximately 24 months
Reported as:
Number · Percentage of Participants
Disease Control Rate (DCR)
Percentage of ParticipantsRivoceranib Plus Best Supportive Care (BSC)Placebo Plus BSC
Disease Control Rate (DCR)40.3 (34.78 to 45.74)13.2 (7.78 to 18.53)
SecondaryChange From Baseline in Global Health Status/Quality of Life (QoL) Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)

EORTC QLQ-C30 is a cancer specific Questionnaire with 30 questions for assessing the health-related QOL of cancer participants. The questionnaire incorporates 5 functional scales, 4 symptom scales, a global QOL scale, and single items for the assessment of additional systems commonly reported by cancer participants. All items are scored on 4-point Likert scales, ranging from 1 ('not at all') to 4 ('very much'), with the exception of 2 items in the global QOL scale which use modified 7-point linear analog scales. A linear transformation was used to standardize all scores and single-items to a scale of 0 to 100. For the functioning scales, a higher score indicated greater functioning and for the symptom scales, a higher score indicated a greater symptom burden.

Time frame:
Baseline, End of Treatment (EOT) (Up to 24 months)
Reported as:
Mean · units on a scale
Change From Baseline in Global Health Status/Quality of Life (QoL) Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)
units on a scaleRivoceranib Plus Best Supportive Care (BSC)Placebo Plus BSC
Change From Baseline in Global Health Status/Quality of Life (QoL) Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)-17.51 ± 22.72-18.01 ± 26.80
SecondaryChange From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Stomach Cancer Specific (EORTC QLQ-STO22) Score

EORTC QLQ-STO22 is a 22-item gastric cancer-specific questionnaire-integrating system for assessing the health-related QOL of gastric cancer participants. Most questions use 4-point scale (1 'Not at all' to 4 'Very much'; 1 question was a yes or no answer). A linear transformation was used to standardize all scores and single-items to a scale of 0 to 100. For the functioning scales, a higher score indicates greater functioning and for the symptom scales, a higher score indicates a greater symptom burden.

Time frame:
Baseline, EOT (Up to 24 months)
Reported as:
Mean · units on a scale
Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Stomach Cancer Specific (EORTC QLQ-STO22) Score
units on a scaleRivoceranib Plus Best Supportive Care (BSC)Placebo Plus BSC
Body Image11.71 ± 29.959.43 ± 35.01
Dyspnea16.64 ± 26.3416.50 ± 24.91
Pain12.72 ± 23.9613.75 ± 21.91
Reflux Symptoms11.46 ± 24.808.31 ± 21.73
Eating Restrictions18.12 ± 26.4517.76 ± 22.89
Anxiety13.69 ± 23.6410.55 ± 26.91
Dry Mouth20.77 ± 33.2211.56 ± 29.15
Taste15.30 ± 32.4614.48 ± 30.18
Hair Loss-15.37 ± 33.71-18.69 ± 30.05
SecondaryChange From Baseline in EuroQol 5-Dimension 5-Level Visual Analogue Scale (EQ-5D-5L VAS) Score

EQ-5D-5L Questionnaire consists of EQ-5D-5L descriptive system and the visual analogue scale (VAS). The descriptive system comprises the 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and each dimension has 5 levels. The VAS is designed to rate the participant's current health state on a scale from 0 to 100, where 0 represents the worst imaginable health state and 100 represents the best imaginable health state.

Time frame:
Baseline, EOT (Up to 24 months)
Reported as:
Mean · units on a scale
Change From Baseline in EuroQol 5-Dimension 5-Level Visual Analogue Scale (EQ-5D-5L VAS) Score
units on a scaleRivoceranib Plus Best Supportive Care (BSC)Placebo Plus BSC
Change From Baseline in EuroQol 5-Dimension 5-Level Visual Analogue Scale (EQ-5D-5L VAS) Score-18.48 ± 19.11-15.36 ± 21.61
SecondaryNumber of Participants Per QOL Dimension Response as Measured by the EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire

EQ-5D-5L Questionnaire comprises the 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and each dimension has 5 levels of response.

Time frame:
EOT (Month 24)
Reported as:
Count of participants · Participants
Number of Participants Per QOL Dimension Response as Measured by the EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire
ParticipantsRivoceranib Plus Best Supportive Care (BSC)Placebo Plus BSC
Mobility: No problems4627
Mobility: Slight problems6027
Mobility: Moderate problems5123
Mobility: Severe problems4317
Mobility: Unable86
Mobility: Missing10052
Self Care: No problems10054
Self Care: Slight problems4722
Self Care: Moderate problems4010
Self Care: Severe problems147
Self Care: Unable77
Self Care: Missing10052
Usual Activities: No problems3624
Usual Activities: Slight problems6136
Usual Activities: Moderate problems5618
Usual Activities: Severe problems4313
Usual Activities: Unable129
Usual Activities: Missing10052
Pain/Discomfort: No pain or discomfort2513
Pain/Discomfort: Slight pain or discomfort6136
Pain/Discomfort: Moderate pain or discomfort6726
Pain/Discomfort: Severe pain or discomfort4719
Pain/Discomfort: Extreme pain or discomfort86
Pain/Discomfort: Missing10052
Anxiety/Depression: Not anxious or depressed4926
Anxiety/Depression: Slightly anxious or depressed6036
Anxiety/Depression: Moderately anxious or depressed6225
Anxiety/Depression: Severely anxious or depressed298
Anxiety/Depression: Extremely anxious or depressed85
Anxiety/Depression: Missing10052

Adverse events

Collected over Up to approximately 36 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rivoceranib Plus Best Supportive Care (BSC)283/307 (92.2%)149/307 (48.5%)299/307 (97.4%)
Placebo Plus BSC134/151 (88.7%)66/151 (43.7%)140/151 (92.7%)
Most frequent serious events
Showing 10 of 129
Most frequent serious events
EventRivoceranib Plus Best Supportive Care (BSC)Placebo Plus BSC
AstheniaGeneral disorders8/3078/151
Abdominal painGastrointestinal disorders15/3073/151
IleusGastrointestinal disorders5/3074/151
CholangitisHepatobiliary disorders2/3074/151
Decreased appetiteMetabolism and nutrition disorders8/3074/151
PneumoniaInfections and infestations8/3070/151
DysphagiaGastrointestinal disorders3/3073/151
Tumour haemorrhageNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/3073/151
PyrexiaGeneral disorders6/3071/151
VomitingGastrointestinal disorders5/3072/151
Most frequent other events
Showing 10 of 31
Most frequent other events
EventRivoceranib Plus Best Supportive Care (BSC)Placebo Plus BSC
Decreased appetiteMetabolism and nutrition disorders132/30745/151
HypertensionVascular disorders106/3075/151
DiarrhoeaGastrointestinal disorders92/30722/151
ProteinuriaRenal and urinary disorders90/30711/151
AnaemiaBlood and lymphatic system disorders64/30741/151
AstheniaGeneral disorders83/30730/151
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders81/3076/151
Abdominal painGastrointestinal disorders78/30730/151
FatigueGeneral disorders77/30716/151
NauseaGastrointestinal disorders72/30734/151

Baseline characteristics

The Intent to Treat (ITT) set consists of data from all participants who were randomized. In the ITT set, participants were included in the group to which they were randomized.

Age, Continuous
Age, Continuous(years)Rivoceranib Plus Best Supportive Care (BSC)Placebo Plus BSCTotal
Mean60.03 ± 11.1159.96 ± 10.6360.01 ± 10.94
Sex: Female, Male
Sex: Female, Male(Participants)Rivoceranib Plus Best Supportive Care (BSC)Placebo Plus BSCTotal
Female6740107
Male241112353
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Rivoceranib Plus Best Supportive Care (BSC)Placebo Plus BSCTotal
Hispanic or Latino505
Not Hispanic or Latino303152455
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Rivoceranib Plus Best Supportive Care (BSC)Placebo Plus BSCTotal
American Indian or Alaska Native000
Asian207105312
Native Hawaiian or Other Pacific Islander000
Black or African American000
White10046146
More than one race000
Unknown or Not Reported112
08

Study locations

95 sites
  • Mayo Clinic Phoenix
    Scottsdale, Arizona 85259, United States
  • Highlands Oncology Group
    Rogers, Arkansas 72758, United States
  • Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
  • Mayo Clinic Cancer Center
    Rochester, Minnesota 55905, United States
  • Hudson Valley Cancer Centre
    Hawthorne, New York 10532, United States
  • Centre Hospitalier Franco-Britannique; Oncologie Médicale
    Levallois-Perret, 92300, France
  • Centre Leon-Berard (CLB)
    Lyon, 69008, France
  • Institut Regional du Cancer Montpellier (ICM)
    Montpellier, 34298, France
  • Centre Antoine-Lacassagne
    Nice, 06189, France
  • Institut Gustave Roussy
    Villejuif, 94805, France
  • Charite - Universitaetsmedizin Berlin - Medizinische Klinik mit Schwerpunkt Haematologie, Onkologie und Tumorimmunologie
    Berlin, 13353, Germany
  • "Institut für Klinisch-Onkologische Forschung (IKF) Krankenhaus Nordwest gGmbH UCT - Universitäres Centrum für Tumorerkrankungen Frankfurt
    Frankfurt, 60488, Germany
  • Facharztzentrum Eppendorf - Haematologisch-Onkologische Praxis Eppendorf (HOPE)
    Hamburg, 20249, Germany
  • Universitätsklinik Marburg, Klinik fur Innere Medizin, Schwerpunkt Haematologie, Onkologie und Immunologie
    Marburg, 35043, Germany
  • Magna Graecia University- Department of Experimental and Clinical Medicine
    Catanzaro, 88100, Italy
  • U.O Di Oncologia Ospedale Degli Infermi
    Faenza, 48018, Italy
  • Fondazione IRCCS-Istituto Nazionale Tumori
    Milano, 20133, Italy
  • Policlinico di Modena-Azienda Ospedaliero Universitaria di Modena.Oncologia ed Ematologia.
    Modena, 41124, Italy
  • Veneto Oncology Institute (IOV-IRCCS), Melanoma & Esophageal Oncology Unit
    Padova, 35128, Italy
  • Ospedale di Piacenza - Oncology and heamatology
    Piacenza, 29121, Italy
  • Ospedale "Felice Lotti"
    Pontedera, 56025, Italy
  • IRCCS/Arcispedale Santa Maria Nuova
    Reggio Emilia, 42123, Italy
  • Rimini Hospital
    Rimini, 47923, Italy
  • Ospedali Riuniti di Ancona - SOD Clinica Oncologica
    Torrette, 60126, Italy
  • Hyogo Cancer Center
    Hyogo, Akasi-city 673-0021, Japan
  • Chiba Cancer Center
    Chiba, Chiba City 260-8717, Japan
  • National Cancer Center Hospital
    Tokyo, Chuo-ku 104-0045, Japan
  • Kyushu University Hospital
    Fukuoka, Higashi-ku 812-8582, Japan
  • National Cancer Center Hospital East
    Chiba, Kashiwa 277-8577, Japan
  • St. Marianna University School of Medicine Hospital
    Kanagawa, Kawasaki-shi 216-8511, Japan
  • Saitama Cancer Center
    Saitama, Kitaadachi-gun 362-0806, Japan
  • Japan Community Health Care Organization Kyushu Hospital
    Fukuoka, Kitakyushu-shi 806-8501, Japan
  • The Cancer Institute Hospital of Japanese Foundation For Cancer Research
    Tokyo, Koto-ku 135-8550, Japan
  • National Hospital Organization Shikoku Cancer Center
    Ehime, Matsuyama 791-0280, Japan
  • Saku Central Hospital Advanced Care Center
    Nagano, Saku-shi 385-0051, Japan
  • Hokkaido University Hospital
    Hokkaido, Sapporo 060-8648, Japan
  • Keio University Hospital
    Tokyo, Shinjuku-ku 160-8582, Japan
  • Osaka University Hospital
    Osaka, Suita 565-0871, Japan
  • Aichi Cancer Center Hospital
    Nagoya, 464-8681, Japan
  • Hallym University Sacred Heart Hospital
    Anyang-si, Gyeonggi-do 14069, Korea, Republic of
  • National Cancer Center
    Goyang-si, Gyeonggi-do 10408, Korea, Republic of
  • Ajou University Hospital
    Suwon-si, Gyonggi-do 16499, Korea, Republic of
  • Inje University Haeundae Paik Hospital
    Busan, 48108, Korea, Republic of
  • Dong-A University Hospital
    Busan, 49201, Korea, Republic of
  • Pusan National University Hospital
    Busan, 49241, Korea, Republic of
  • Chungbuk National University Medical Center
    Chuncheon, 41404, Korea, Republic of
  • Chungbuk National University Hospital
    Chungbuk, 54907, Korea, Republic of
  • Kyungpook National University Medical Center
    Daegu, 41404, Korea, Republic of
  • Keimyung University Dongsan Medical Center
    Daegu, 41931, Korea, Republic of
  • Yeungnam University Medical Center
    Daegu, 42415, Korea, Republic of
  • Chungnam National University Hospital
    Daejeon, 35015, Korea, Republic of
  • Seoul National University Bundang Hospital
    Gyeonggi-do, 13620, Korea, Republic of
  • Gachon University Gil Medical Center
    Incheon, 21555, Korea, Republic of
  • Korea University Anam Hospital
    Seoul, 02841, Korea, Republic of
  • Severence Hospital, Yonsei University Health System
    Seoul, 03722, Korea, Republic of
  • Veterans Health Service (VHS) Medical Center
    Seoul, 05368, Korea, Republic of
  • ASAN Medical Center
    Seoul, 05505, Korea, Republic of
  • Gangnam Severance Hospital
    Seoul, 06273, Korea, Republic of
  • Samsung Medical Center
    Seoul, 06351, Korea, Republic of
  • Korea University Guro Hospital
    Seoul, 08308, Korea, Republic of
  • Ulsan University Hospital
    Ulsan, 44033, Korea, Republic of
  • Szpital Uniwersytecki w Krakowie, Odział Kliniczny Onkologii
    Kraków, 31-501, Poland
  • Centrum Onkologii-Instytut im. Marii Skłodowskiej-Curie, Klinika Gastroenterologii Onkologicznej
    Warszawa, 02-781, Poland
  • Saint Constantin Hospital (TEO HEALTH SA)
    Brasov, 500091, Romania
  • Institutul Oncologic "Prof. Dr. Ion Chiricuta" Cluj-Napoca, Sectia de Radioterapie I
    Cluj-Napoca, 400015, Romania
  • S.C. Medisprof S.R.L.
    Cluj-Napoca, 400058, Romania
  • Centrul de Oncologie "Sf. Nectarie", Sectia de Oncologie Medicala
    Craiova, 200347, Romania
  • State Budgetary Healthcare Institution of Arkhangelsk Region "Arkhangelsk Clinical Oncology Dispensary"
    Arkhangelsk, 163045, Russian Federation
  • State Healthcare Institution "Kursk Regional Clinical Oncology Dispensary"
    Kursk, 305035, Russian Federation
  • Omsk regional clinical oncology center
    Omsk, 644013, Russian Federation
  • Budgetary Healthcare Institution of Orel Region "Orel Oncology Dispensary"
    Oryol, 302020, Russian Federation
  • State Budgetary Healthcare Institution of Stavropol Territory "Pyatigorsk Oncology Dispensary"
    Pyatigorsk, 357502, Russian Federation
  • Ogarev Mordovia State University
    Saransk, 430032, Russian Federation
  • Federal State Budgetary Educational Institution of Higher Education "Academician I.P. Pavlov First St. Petersburg State Medical University" of the Ministry of Heaithcare of the Russian Federation
    St. Petersburg, 197022, Russian Federation
  • State Budgetary Healthcare Institution "Republican Clinical Oncology Dispensary"
    Ufa, 450054, Russian Federation
  • Taipei Veterans General Hospital
    Taipei, Beitou Dist 11217, Taiwan
  • Chang Gung Memorial Hospital - Linko Branch
    Taoyuan, Kuei Shan Hsiang 333, Taiwan
  • Chi Mei Medical Center - LiouYing Branch
    Tainan, Liuying DIst 736, Taiwan
  • Chang Gung Memorial Hospital - Kaohsiung Branch
    Kaohsiung, Niaosong Dist 83301, Taiwan
  • Kaohsiung Medical University Hospital
    Kaohsiung, Sanmin Dist 80708, Taiwan
  • China Medical University Hospital
    Taichung, Taichung City 40447, Taiwan
  • National CHeng Kung University Hospital
    Tainan, Tainan City 70403, Taiwan
  • National Taiwan University Hospital
    Taipei, Zhongzheng Dist 100, Taiwan
  • Dnipropetrovsk Medical Academy, Department of Oncology
    Dnipro, 49102, Ukraine
  • Communal Institution "Ivano-Frankivsk Regional Oncological Center"
    Ivano-Frankivsk, 76000, Ukraine
  • Communal Institution "Kharkiv Regional Clinical Oncology Center ", Chemotherapy department #1, Medical Academy of Postgraduate Education, Oncology and Pediatric Oncology
    Kharkiv, 61070, Ukraine
  • Kherson Regional Oncological Dispensary
    Kherson, 73035, Ukraine
  • Municipal Institution Kryvyi Rig Oncology Dispensary", Chemotherapy Department
    Kryvyi Rih, 50048, Ukraine
  • Municipal Institution "Kyiv City Clinical Oncological Center"
    Kyiv, 03115, Ukraine
  • Communal Institution "Transcarpathian Regional Clinical Oncological Center"
    Uzhhorod, 88014, Ukraine
  • Communal Institution "Vinnytsia Regional Clinical Oncology Dispensary"
    Vinnytsia, 21029, Ukraine
  • State institution "Zaporizhzhia Medical Academy of Postgraduate Education MOH Ukraine", Department of oncology based on Municipal Institution "Zaporizhzhia Regional Clinical Oncology Dispensary" Zaporizhzhia Regional Assembly
    Zaporizhzhia, 69040, Ukraine
  • Royal Marsden Hospital London
    London, SW3 6JJ, United Kingdom
  • The Christie NHS Foundation Trust
    Manchester, M20 4BX, United Kingdom
  • Royal Marsden Hospital Surrey
    Sutton, SM2 5PT, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2017 to primary completion in Feb 2019, 23 months.

Results were first posted in Jul 2022, 3 years 4 months after primary completion.

Of 45 industry-sponsored phase 3 interventional studies under Stomach Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 55. This study's 23 months is below that.

Counting every sponsor, half of 118 studies reached it within 52 months; a quarter within 39 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 24, 2017
First posted
Feb 3, 2017
StartActual
Mar 14, 2017
Primary completionActual
Feb 15, 2019
CompletionActual
Sep 23, 2020
Results first posted
Jul 8, 2022
Last update
Jul 8, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03042611
Lead sponsor
Elevar Therapeutics
Responsible party
Sponsor
First posted
Feb 3, 2017
Start date
Mar 14, 2017
Primary completion
Feb 15, 2019
Completion
Sep 23, 2020
Results posted
Jul 8, 2022
Last update
Jul 8, 2022

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apatinib

Start the discussion